Virion Therapeutics

About:

Virion Therapeutics is a science-driven company developing innovative immune-based treatments for virally-associated cancers.

Website: https://www.viriontx.com

Top Investors: Keiretsu Capital, Keiretsu Forum, Alliance of Angels, Life Science Angels, Puget Sound Venture Club

Description:

Virion Therapeutics is a science-driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections. Their vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potently and sustained T cell-mediated immune responses against transformed or infected cells, thereby targets common diseases with unmet medical needs. Each component comprising chimeric vaccine candidates has completed pre-clinical testing that allows for their translation into clinical trials for several different indications. Guided by their scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics was founded in 2018 and is headquartered in Newark, Delaware.

Total Funding Amount:

$14.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Newark, Delaware, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)viriontx.com

Founders:

Andrew D. Luber, Hildegund Ertl

Number of Employees:

11-50

Last Funding Date:

2021-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai